We are live on ! Find out more
DYN icon

Dyne Therapeutics

193 hedge funds and large institutions have $3.92B invested in Dyne Therapeutics in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 79 increasing their positions, 46 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

527% more call options, than puts

Call options by funds: $6.11M | Put options by funds: $973K

124% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 21

72% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 46

45% more capital invested

Capital invested by funds: $2.71B → $3.92B (+$1.21B)

40% more funds holding in top 10

Funds holding in top 10: 1014 (+4)

14% more funds holding

Funds holding: 169193 (+24)

3.01% less ownership

Funds ownership: 116.41%113.4% (-3%)

Holders
193
Holders Change
+24
Holders Change %
+14.2%
% of All Funds
2.79%
Holding in Top 10
14
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+40%
% of All Funds
0.2%
New
47
Increased
79
Reduced
46
Closed
21
Calls
$6.11M
Puts
$973K
Net Calls
+$5.13M
Net Calls Change
+$11.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Federated Hermes
26
Federated Hermes
Pennsylvania
$42.9M +$3.34M +114,888 +10%
OCA
27
Octagon Capital Advisors
New York
$41.7M -$1.81M -62,147 -5%
AC
28
Armistice Capital
New York
$34.3M -$846K -29,109 -3%
ACH
29
ArrowMark Colorado Holdings
Colorado
$32.4M +$15.6M +537,000 +140%
O
30
OrbiMed
New York
$25M
BBA
31
Baker Bros. Advisors
New York
$23.7M +$11.2M +387,096 +136%
N
32
Nuveen
North Carolina
$22.4M +$2.87M +98,875 +18%
Northern Trust
33
Northern Trust
Illinois
$21.9M +$2.11M +72,604 +13%
Charles Schwab
34
Charles Schwab
California
$21.2M +$4.05M +139,540 +30%
Morgan Stanley
35
Morgan Stanley
New York
$19.7M -$11.7M -403,112 -42%
CS
36
Candriam SCA
Luxembourg
$18.8M -$4.14M -142,351 -21%
EAM
37
Eventide Asset Management
Massachusetts
$17.1M +$14.1M +485,000 New
LP
38
LMR Partners
United Kingdom
$16.8M +$13.9M +477,000 New
RSCM
39
Rock Springs Capital Management
Maryland
$16.3M +$267K +9,204 +2%
Lord, Abbett & Co
40
Lord, Abbett & Co
New Jersey
$16M +$13.1M +452,213 New
EC
41
EcoR1 Capital
California
$15.1M
VVA
42
Vida Ventures Advisors
Massachusetts
$14.4M
FLAM
43
First Light Asset Management
Minnesota
$13.5M +$8.03M +276,485 +261%
Point72 Asset Management
44
Point72 Asset Management
Connecticut
$12.6M -$9.56M -328,916 -48%
WA
45
Wasatch Advisors
Utah
$11.8M -$2.39M -82,179 -20%
Ensign Peak Advisors
46
Ensign Peak Advisors
Utah
$11M -$8.68M -298,541 -49%
Bank of New York Mellon
47
Bank of New York Mellon
New York
$11M +$3.12M +107,233 +52%
Pictet Asset Management
48
Pictet Asset Management
Switzerland
$10.4M +$8.56M +294,748 New
Marshall Wace
49
Marshall Wace
United Kingdom
$9.65M +$6.39M +219,862 +409%
LGM
50
Logos Global Management
California
$9.35M -$42.6M -1,465,000 -85%

DYN Hedge Fund Activity: Q2 2024 in Review

193 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q2 2024, worth a combined $3.92B — up 45% from $2.71B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new DYN positions and 21 closed out — a net gain of 26 holders — while 79 added to existing stakes and 46 trimmed.

The largest buyer was RTW Investments, adding an estimated $95.8M. The largest seller was MPM Asset Management, cutting an estimated $54.9M.

  • 193 institutional investors held Dyne Therapeutics (DYN) as of Q2 2024, up from 169 in Q1 2024.
  • Funds reported $3.92B of Dyne Therapeutics stock for Q2 2024, up 45% quarter-over-quarter.
  • 47 funds opened new Dyne Therapeutics positions in Q2 2024 and 21 closed out, a net change of +26 holders.
  • The largest Dyne Therapeutics buyer in Q2 2024 was RTW Investments, an estimated $95.8M added.
  • The largest Dyne Therapeutics seller in Q2 2024 was MPM Asset Management, an estimated $54.9M sold.

Based on aggregated 13F filings for Q2 2024.